{"organizations": [], "uuid": "66af0ba935815543dd4da507a223194508b4a4b5", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180201.html", "section_title": "Archive News &amp; Video for Thursday, 01 Feb 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-cosmo-pharmaceuticals-and-pharmasc/brief-cosmo-pharmaceuticals-and-pharmascience-establish-license-and-supply-agreement-idUSFWN1PQ1JC", "country": "US", "domain_rank": 408, "title": "BRIEF-Cosmo Pharmaceuticals And Pharmascience Establish License And Supply Agreement‍​", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.497, "site_type": "news", "published": "2018-02-01T14:05:00.000+02:00", "replies_count": 0, "uuid": "66af0ba935815543dd4da507a223194508b4a4b5"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-cosmo-pharmaceuticals-and-pharmasc/brief-cosmo-pharmaceuticals-and-pharmascience-establish-license-and-supply-agreement-idUSFWN1PQ1JC", "ord_in_thread": 0, "title": "BRIEF-Cosmo Pharmaceuticals And Pharmascience Establish License And Supply Agreement‍​", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "cosmo", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}, {"name": "gdynia newsroom", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Feb 1 (Reuters) - COSMO PHARMACEUTICALS NV:‍​\n* COSMO PHARMACEUTICALS AND PHARMASCIENCE ESTABLISH LICENSE AND SUPPLY AGREEMENT FOR ELEVIEW, METHYLENE BLUE MMX, RIFAMYCIN MMX AND QOLOTAG FOR CANADA​\n* ‍AGREEMENT ENTAILS AN UP-FRONT PAYMENT TO COSMO OF TOTAL CA$ 5 MILLION​\n* ‍ADDITIONAL COMMERCIAL MILESTONE PAYMENTS UPON REACHING CERTAIN ANNUAL SALES THRESHOLDS, AND HIGH DOUBLE-DIGIT ROYALTIES​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-02-01T14:05:00.000+02:00", "crawled": "2018-02-02T12:45:22.040+02:00", "highlightTitle": ""}